Premium
Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t‐cell acute lymphoblastic leukemia and ABL1 amplification
Author(s) -
Crombet Ofelia,
Lastrapes Kelly,
Zieske Arthur,
MoralesArias Jaime
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23327
Subject(s) - dasatinib , medicine , abl , chemotherapy , tyrosine kinase , tyrosine kinase inhibitor , lymphoblastic leukemia , leukemia , oncology , cancer research , imatinib , cancer , myeloid leukemia , receptor
T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐generation tyrosine kinase inhibitor, directly targets the BCR‐ABL gene. We describe a pediatric case of T‐cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy. Pediatr Blood Cancer 2012;59:333–334. © 2011 Wiley Periodicals, Inc.